ArticleInternational journal of nanomedicine2024
Antioxidant Carbon Dots Nanozyme Loaded in Thermosensitive in situ Hydrogel System for Efficient Dry Eye Disease Treatment.
Article in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Quantum Dots in Ocular Surface: A Systematic Review.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyPooled it
- A ROS-Responsive and Mucoadhesive Thermosensitive Hydrogel Encapsulated with Mizoribine for Synergistic Dry Eye Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Surface-Engineered Nitrogen-Doped Carbon Dots with Quaternary Ammonium for Fluorescent Sensing, Antioxidant, and Antibacterial Applications.ACS omega · 2026Article
- Microenvironment-Responsive Drug Delivery Systems for Ocular Surface Diseases: Mechanisms, Applications, and Translational Challenges.Small science · 2026Review
- Rebuilding Ocular Surface Lubrication with a Light-Triggered Hydration-Lubricating Nanoplatform for Dry Eye Disease Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- A dual-function rebamipide cubogel for enhanced ocular penetration and tear film restoration: optimization, safety, and in-vivo evaluation.Drug delivery and translational research · 2026Article
- Next-generation smart ophthalmic biomaterials: From passive response to active interaction and closed-loop control.Bioactive materials · 2026Review
- Advances in loading-release-repair strategies of hydrogels for anterior segment disease therapy.Frontiers in immunology · 2026Review
- Recent Achievements and Perspectives in Smart Nano-in-Micro Platforms for Ocular Disease Treatment.International journal of nanomedicine · 2025Review
- Recent Advances in Smart Polymers-Based Therapeutics in Ophthalmology.International journal of nanomedicine · 2025Review
- Advances in adhesive hydrogels applied for ophthalmology: An overview focused on the treatment.Theranostics · 2025Review
- The recent research progress in the application of the nanozyme-hydrogel composite system for drug delivery.Drug delivery · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Dry eye disease (DED) is a multifactorial ocular surface disease with a rising incidence. Therefore, it is urgent to construct a reliable and efficient drug delivery system for DED treatment. Methods: In this work, we loaded C-dots nanozyme into a thermosensitive in situ gel to create C-dots@Gel, presenting a promising composite ocular drug delivery system to manage DED. Results: This composite ocular drug delivery system (C-dots@Gel) demonstrated the ability to enhance adherence to the corneal surface and extend the ocular surface retention time, thereby enhancing bioavailability. Furthermore, no discernible ocular surface irritation or systemic toxicity was observed. In the DED mouse model induced by benzalkonium chloride (BAC), it was verified that C-dots@Gel effectively mitigated DED by stabilizing the tear film, prolonging tear secretion, repairing corneal surface damage, and augmenting the population of conjunctival goblet cells. Conclusion: Compared to conventional dosage forms (C-dots), the C-dots@Gel could prolong exhibited enhanced retention time on the ocular surface and increased bioavailability, resulting in a satisfactory therapeutic outcome for DED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.